VJOncology is committed to improving our service to you

GU Cancers 2018 | Exciting potential of pembrolizumab combined with axitinib for kidney cancer

VJOncology is committed to improving our service to you

Elizabeth Plimack

Elizabeth Plimack, MD, from Fox Chase Cancer Center, Philadelphia, PA, gives an overview of a study (NCT02133742) looking at pembrolizumab combined with axitinib for the first-line treatment of advanced kidney cancer. Speaking at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Plimack hopes this combination can become the new frontline standard of care in renal oncology.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter